We have analyzed the modulation of amyloid (3-protein precursor (APP) gene expression in human umbilical vein endothelial cells (HUVEC). The level of the APP mRNA transcripts increased as HUVEC reached confluency. In confluent culture the half-life of the APP mRNA was 4 hr. Treatment of the cells with human recombinant interleukin 1 (IL-1), phorbol 12-myristate 13-acetate, or heparin-binding growth factor 1 enhanced the expression of APP gene in these cells, but calcium ionophore A23187 and dexamethasone did not. The protein kinase C inhibitor 1-(isoquinolinsulfonyl)-2-methylpiperazine (H7) inhibited IL-1-mediated increase of the level of APP transcripts. To map IL-1-responsive elements of the APP promoter, truncated portions of the APP promoter were fused to the human growth hormone reporter gene. The recombinant plasmids were transfected into mouse neuroblastoma cells, and the cell medium was assayed for the human growth hormone. A 180-base-pair region of the APP promoter located between position -485 and -305 upstream from the transcription start site was necessary for IL-1-mediated induction of the reporter gene. This region contains the upstream transcription factor AP-1 binding site. These results suggest that IL-1 upregulates APP gene expression in HUVEC through a pathway mediated by protein kinase C, utilizing the upstream AP-1 binding site of the APP promoter.
family of proteins, each containing a 42-amino acid fragment called amyloid 3 or A4 protein, that is found in brains and the cerebrovasculature of Alzheimer disease, Down syndrome, hereditary cerebral hemorrhage (Dutch type), and aging (1) (2) (3) (4) (5) . The APP gene is transcriptionally active in a variety of tissues, highly conserved in evolution, maps to human chromosome 21 (6) (7) (8) (9) (10) , and probably has no mutations associated with Alzheimer disease (11, 12) . Transcripts containing three similar but nonidentical open reading frames have been identified (13) (14) (15) (16) (17) . In situ hybridization studies show a very complex pattern of the APP gene expression in brain (18) (19) (20) (21) (22) (23) .
Different levels of APP mRNAs were detected in neurons, some glial cells, and cells that compose blood vessels, presumably some endothelial cells (23) . The detection of APP mRNA in these cells strengthens the possibility that at least one form of amyloid 83-protein-cerebrovascular-could originate locally from blood vessels (24, 25) .
The importance ofunderstanding the regulation ofthe APP gene is underscored by two observations. First, there are differences between Alzheimer disease patients and controls in the levels of APP mRNAs in certain brain regions (19, 23, (26) (27) (28) (29) (30) . Second, the difference in the level of APP mRNAs between trisomy 21 Down-syndrome patients and controls having two chromosomes 21 was higher than the expected 3:2 ratio (9). In the absence of structural mutations, aberrant levels of the precursor protein may contribute to pathology. These observations suggest that there is aberrant regulation of the APP gene in Alzheimer disease and Down syndrome patients. Further, the striking similarity of neuropathological changes in Alzheimer disease and Down syndrome implies a common multistep mechanism ofamyloid formation that may involve changes in the APP gene expression as a required step.
The goal of this study was to identify factors that regulate the level of APP mRNAs in human endothelial cells. We describe here the expression of APP mRNA transcripts by human endothelial cells, the responsiveness of the APP gene to interleukin 1 (IL-1) and several other mediators, and a localization of the cis-acting regulatory element that plays a key role in the induction of the APP gene expression by IL-1. These gels were stained with ethidium bromide at 0.5 ,ug/ml and photographed to verify that each lane contained an approximately equal amount of undegraded RNA. After transfer to Zeta-Probe nylon membranes (Bio-Rad), the membranes were hybridized to 32P-labeled APP-specific probes. One probe, a 1.05-kilobase (kb) EcoRI fragment of a phage A Am4 APP cDNA clone (6), detected a common region in APP mRNAs. Probes were labeled by using a randomly primed DNA labeling kit from Boehringer Mannheim (34) . After hybridization the membranes were washed under conditions of high stringency as described (35) except that prehybridization solutions contained 2% sodium dodecyl sulfate (SDS). After exposure of hybridization membranes to XAR-5 film (Kodak), they were stripped by incubation in 0.1% SDS/20% formamide at 80'C for 15 min. Stripped filters were rehybridized to a 1.0-kb human f-actin or an 18S ribosomal RNA probe to verify quantitation of RNA. The f3-actin probe was a gift from Stephen Chang (National Institute of Neurological and Communicative Disorders and Stroke). Autoradiograms were scanned with a dual-wavelength densitometer (Shimadzu, Kyoto, Japan).
MATERIALS AND METHODS
Plasmid Constructions. Phage A clone 783 containing the human APP gene promoter was isolated from a chromosome 21 genomic library (ATCC 57743; R.J.D. and M.P.V., unpublished data). The APP promoter was first cloned into the EcoRI site of pUC19, followed by subcloning into the BamHI site of pOGH plasmid, which lacks a promoter but contains five exons of the gene for hGH (36) . One construct, pCLL-EB, spans position numbers -2830 to + 101 [adenosine in the first AUG of APP695 cDNA (7) is at position + 147], while the second, pCLL-BE, contains the same fragment in the inverse (+101 to -2837) orientation. Two additional clones were derived from the pCLL-EB construct by restriction digestion with HindIII or with Xba I endonucleases followed by religation of the shortened plasmids and were named pCLL-HB (-485 to +101) and pCLLXB (-305 to +101), respectively. All positions are numbered according to Salbaum et al. (37) .
RESULTS
To evaluate the effect of growth on APP gene expression, the levels ofAPP mRNA transcripts were determined in HUVEC cultures grown at various densities. The expression of the APP mRNA transcripts was minimal during phases of active growth (low cell density) and increased in confluent cultures (Fig. 1A) . Cells harvested 1 day after subculture at a 1:2 or 1:4 split ratio demonstrated the equally low level of the APP mRNA transcripts. Thus, the density at which the cells were grown does not appear to influence APP expression.
To study the turnover rate of APP mRNA transcripts, confluent cultures of HUVEC were treated with actinomycin D, and RNA was isolated from the cells harvested at various time points, electrophoresed, and probed with the APP probe. The quantity of APP mRNA transcripts decreased logarithmically with a half-life of -4 hr (Fig. 1B) . Changes in the level of the APP mRNA transcripts after treatment with several mediators known to modulate gene expression in vascular endothelial cells are shown in Fig. 2A . PMA, IL-1, Fig. 2C . IL-1 had a relatively rapid onset of action, reaching peak levels between 6 and 24 hr. The effect of IL-1 then began to level off. In contrast, HBGF-1 had a delayed onset and more prolonged course of action.
The increase in the level of the APP mRNA by PMA suggests that activation of the protein kinase C pathway (38) may play an important role in the regulation of APP. It is known that in some cell systems, IL-1 acts through the protein kinase C pathway (39) . It seemed likely that the effects of IL-1 on the levels of the APP mRNA transcripts in HUVEC were also mediated by protein kinase C. Therefore, the protein kinase C inhibitor H7 (40) was used in combinaNeurobiology: GoIdgaber et al. tion with IL-1 to determine whether this pathway is involved in APP gene regulation. The H7 inhibitor did eliminate the IL-1-induced increase in the level of the APP mRNAs in a dose-dependent manner (Fig. 2D) .
The promoter region of the APP gene has recently been identified (37) . The APP promoter region does not contain a TATA box, has a high G+C content and a heat shock control element, and contains two regions with homology to the consensus sequence recognized by the transcription factor AP-1. However, the functionality of these AP-1 sites is not known. To map the APP promoter-active region that is responsive to the induction by IL-1, a number of the APP promoter fragments were fused with the hGH cDNA (Fig.  3A) that was subcloned into the pOGH plasmid (36) , and each of the constructs was separately transfected into AB-1 mouse neuroblastoma cells. The cells were grown with or without IL-1. The quantity of the released hGH was measured in the medium of the transfected AB-1 cells. The results show that IL-1 can induce hGH gene expression that is driven by the APP promoter (Fig. 3B) . It also shows that the removal of the 180-bp fragment containing the upstream AP-M binding site (position -350) eliminated the induction of the reporter hGH gene by IL-1.
DISCUSSION
The experiments described above suggest that the level of expression of the APP mRNA transcripts in human endothelial cells can be modulated by PMA, IL-1, and HBGF-1 but not by calcium ionophore A23187 or dexamethasone. IL-1 is a major modulator of the immune response to trauma, infection, or inflammation (41) . Endothelial cells exposed to IL-1 synthesize prostaglandins and platelet-activating factor (40) and show accelerated release of von Willebrand factor (42) . Interestingly, a significant increase in formation of prostaglandin D2 in frontal cortex of Alzheimer disease patients was described recently (43) . Systemic administration of IL-1 results in increased hepatic production of serum amyloid A, a precursor of the amyloid fibrils found in a secondary amyloidosis (44) . IL-1 is expressed in the central nervous system (45) where it is thought to play a number of roles, including a hypothalamic acute-phase response (46) and a stimulation of astroglial proliferation after brain injury (47) . Because of the diverse biological activities of IL-1, the observation that IL-1 enhances expression of the APP mRNA transcripts in human endothelial cells is of particular importance. Griffin et al. (48) Proc. Natl. Acad. Sci. USA 86 (1989) ." mRNAs induced by IL-1 was blocked by H7, an inhibitor of protein kinase C (38). Thus, it is possible that this induction may be mediated by the protein kinase C pathway. Interestingly, the topological distribution of the y isotype of protein kinase C immunoreactivity (38) and the APP mRNA (18) and immunoreactivity (49, 50) is similar in the brain.
The APP promoter region responsive to the IL-1 modulation contains one of the two potential AP-1 binding sites. While our data provide evidence for the functionality of one of these sites, it remains to be determined if this site is the only one critical for APP gene induction. These results also suggest that the presence of the downstream AP-1 binding site (position -45) is not sufficient for the IL-1-induced changes in the mRNA level of the APP gene. However, these data agree with the H7 inhibition studies and argue that IL-1 regulates APP gene expression in human endothelial cells by a mechanism mediated by protein kinase C utilizing an AP-1 binding site in the APP gene promoter region.
Although the origin ofamyloid in Alzheimer disease, Down syndrome, hereditary cerebral hemorrhage (Dutch type), and aging remains unsettled, the vascular endothelial cell model provides a very useful experimental system for the study of the regulation of expression of the APP gene. The observation that APP mRNA transcript expression is enhanced by several well-studied factors provides useful information about the functional regulation of the APP gene. Thus, the potential involvement of mediators of growth and inflammation in the development of cerebral amyloidosis is an area that warrants further study.
